Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation (NYSE: WAT) is a global leader in the field of analytical instruments and software solutions. For nearly six decades, the company has pioneered advancements in chromatography, mass spectrometry, and thermal analysis, catering to life, materials, and food sciences. Headquartered in Milford, Massachusetts, Waters Corp. operates directly in 35 countries, supported by approximately 8,000 employees and 15 manufacturing facilities globally.
Waters' main business segments include Waters, TA Instruments, VICAM, ERA, and Nonlinear Dynamics. The company's diverse product portfolio features ultra-performance liquid chromatography (UPLC), high-performance liquid chromatography (HPLC), chromatography columns, mass spectrometry systems, and laboratory informatics solutions. These innovations empower laboratory-dependent organizations to achieve advancements in healthcare, environmental management, food safety, and water quality.
Waters Corporation serves a wide array of customers, including biopharmaceutical companies (57% of sales), industrial clients (31% of sales), and academic/government institutions (12% of sales). The company’s products are available in over 100 countries, ensuring a broad market reach.
Recent achievements include the launch of new accessories for TA Instruments Discovery Hybrid Rheometers, designed for battery formulation analysis, and the introduction of Oasis WAX/GCB and GCB/WAX Cartridges for PFAS analysis. These innovations reflect the company’s commitment to addressing emerging scientific challenges and regulatory requirements. Additionally, Waters continues to enhance its mass spectrometry capabilities with products like the ACQUITY QDa II Mass Detector and the Xevo MRT MS, aimed at accelerating research in pharmaceuticals, food, chemicals, and materials.
Financially, Waters Corporation reported first-quarter 2024 sales of $637 million, with a strategic focus on innovation and operational efficiency. Despite a 7% decrease in sales compared to the previous year, the company remains optimistic about future growth, driven by new product launches and higher growth areas.
Waters Corporation stands as a pivotal player in the analytical instruments industry, consistently driving scientific advancements and operational excellence.
Waters Corporation (NYSE: WAT) reported Q3 2022 sales of $709 million, reflecting a 7% increase as reported and 15% in constant currency. Key highlights include a 21% surge in instrument sales and strong revenue growth across all major geographies, particularly a 23% increase in China. Recurring revenues rose 10% in constant currency. GAAP EPS remained stable at $2.60, while non-GAAP EPS slightly declined to $2.64. Waters raised its full-year 2022 sales growth guidance to 11.5%-12%, despite a 6% unfavorable currency impact. For Q4, it projects sales growth of 6%-8% and non-GAAP EPS of $3.66-$3.76, factoring in currency headwinds.
Waters Corporation has launched the Extraction+ Connected Device, which automates solid phase extraction (SPE) methods, significantly reducing sample preparation time by up to four hours per sample set. This innovation, compatible with the Andrew+ Pipetting Robot and controlled through OneLab Software, minimizes user variability and enhances assay reproducibility. The device is now available globally, marking a step forward in laboratory efficiency for biological, food, forensic, and environmental applications.
Waters Corporation (NYSE:WAT) announced a multi-year investment of up to €6 million, supported by IDA Ireland, to enhance its research and development operations in Wexford, Ireland. This expansion aims to create new scientific jobs and focus on clinical diagnostic solutions. Waters commemorates its 25th anniversary in Ireland, reinforcing its commitment to advancing mass spectrometry technologies for early disease detection. The Wexford facility is vital for manufacturing in-vitro diagnostic systems and aims to improve diagnostic accuracy for various medical conditions.
Waters Corporation (NYSE:WAT) will announce its Q3 2022 financial results in a conference call on November 1, 2022, at 8:00 a.m. ET. The presentation will be accessible through a live webcast on Waters’ investor relations website. A replay option will be available until November 15, 2022, at midnight ET. Waters Corporation has over 60 years of experience in analytical instruments and software, serving various sectors, including life sciences and materials, with a workforce of more than 7,800 employees.
Waters Corporation (NYSE:WAT) has launched advanced powder rheology capabilities for its HR Rheometer, enhancing its versatility in characterizing liquids, solids, and powders. The new SmartSwap™ tooling allows quick transitions between liquid and powder measurements in just 10 seconds, improving sample preparation speed by three times compared to competitors. This innovative technology supports industries like lithium-ion batteries and pharmaceuticals, ensuring accurate data for optimizing materials and processing. The powder rheology accessory is available for existing or new HR Rheometers.
Waters Corporation announced the opening of a new
Waters Corporation (NYSE:WAT), under CEO Udit Batra, will join the Bank of America 2022 Global Healthcare Conference in London on September 14, 2022, at 9:05 AM BST. Investors can tune into the event via a live webcast on the company’s investor relations website. A recorded replay will be accessible for 30 days post-event. With over 60 years of experience, Waters is a leader in analytical instruments and software, employing 7,800 staff across 35 countries and operating 14 manufacturing facilities.
Waters Corporation (NYSE: WAT) reported second-quarter 2022 sales of $714 million, a 5% increase from the previous year and 10% in constant currency. Instrument sales rose 12% in constant currency, driven by robust performance across product lines. Recurring revenues grew by 8% in constant currency. GAAP EPS was $2.72 and non-GAAP EPS increased 6% to $2.75. For the first half of 2022, sales were $1,405 million, up 9% as reported, with full-year 2022 guidance raised, anticipating 9.5% to 10.5% constant currency sales growth.
Waters Corporation (NYSE:WAT) announced its collaboration with the Plant Protein Innovation Center at the University of Minnesota to advance plant-based protein science. The partnership will leverage Waters’ ACQUITY Premier UPLC System to establish a standard workflow for amino acid analysis, vital for evaluating alternative proteins. With projections showing that plant proteins could secure an 11% market share by 2035, Waters aims to support the transition to healthier and sustainable dietary options while addressing climate change and food security challenges.
Waters Corporation (NYSE:WAT) will host its Q2 2022 financial results conference call on August 2, 2022, at 8:00 a.m. ET. The event will be accessible via a live webcast on Waters' investor relations site, with a replay available until August 16, 2022. Waters, a leader in analytical instruments and software, has been innovating in chromatography and mass spectrometry for over 60 years, employing more than 7,800 people and operating in over 35 countries.
FAQ
What is the current stock price of Waters (WAT)?
What is the market cap of Waters (WAT)?
What industries does Waters Corporation serve?
What are some of Waters Corporation's recent product launches?
How does Waters Corporation contribute to scientific advancements?
What is the significance of the TA Instruments Discovery Hybrid Rheometers?
How is Waters Corporation performing financially?
Where is Waters Corporation headquartered?
How many employees does Waters Corporation have?
What are TA Instruments' main products?
What is the significance of the Oasis WAX/GCB Cartridges?
How can I access Waters Corporation's financial results?
